# A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

> **NCT07198321** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Genfleet Therapeutics (Shanghai) Inc.** · enrollment: 450 (estimated)

## Conditions studied

- Cancer
- PDAC
- CRC (Colorectal Cancer)
- NSCLC

## Interventions

- **DRUG:** GFH276

## Key facts

- **NCT ID:** NCT07198321
- **Lead sponsor:** Genfleet Therapeutics (Shanghai) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2027-09-22
- **Final completion:** 2027-12-30
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07198321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07198321, "A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07198321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*